Serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in COVID-19 patients.

Front Med (Lausanne) · 2024 · PMC11790429 · PMID 39906348

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Conversely, biglycan levels showed an increasing trend, being 66.15 ± 2.22 pg/mL in the control group, 70.02 ± 1.57 pg/mL in moderate COVID-19 patients, and 75.88 ± 1.97 pg/mL in severe COVID-19 patients, with an ANOVA p value of 0.0042.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.